FDA announcements or GSK press releases

British GSK Acquires Experimental Lupus Drug from Chimagen Biosciences for Up to $850 Million

Oct 29, 2024, 12:27 PM

British drugmaker GSK has entered into an agreement to acquire CMG1A46, an experimental drug from Chinese biotech firm Chimagen Biosciences, for up to $850 million. This acquisition includes a $300 million upfront payment and aims to expand GSK's pipeline of potential treatments for lupus. The drug, CMG1A46, is a clinical-stage dual CD19 and CD20-targeted T cell-engager, which is expected to enhance GSK's immunology portfolio.